Adagene (ADAG) Liabilities and Shareholders Equity (2019 - 2025)

Adagene's (ADAG) quarterly Liabilities and Shareholders Equity came in at $78.3 million in Q4 2025, down 12.33% year-on-year from $89.3 million in Q4 2024, and up 17.66% on a QoQ basis from $66.5 million in Q2 2025.

Adagene (ADAG) Liabilities and Shareholders Equity (2019 - 2025) Analysis & Trends

Adagene (ADAG) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $78.3 million in Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 12.33% year-over-year to $78.3 million in Q4 2025; TTM through Dec 2025 was $334.8 million, a 9.5% increase from a year earlier, with the FY2025 full-year figure at $78.3 million, down 12.33% from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 stood at $78.3 million, up from $66.5 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for ADAG reached as high as $217.9 million in Q2 2021 and fell as low as $135.3 in Q2 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $101.0 million across 5 years, with a median of $95.0 million in 2024.
  • Across the five-year window, Liabilities and Shareholders Equity slumped 100.0% in 2022 and surged 74484683.94% in 2024, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $189.5 million in 2021, then retreated by 19.58% to $152.4 million in 2022, then slipped by 24.06% to $115.7 million in 2023, then slipped by 22.86% to $89.3 million in 2024, then declined by 12.33% to $78.3 million in 2025.
  • Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $78.3 million in Q4 2025, $66.5 million in Q2 2025, and $89.3 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Adagene 198.85 Mn 198.85 Mn - 78.26 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 78.26 Mn
Jun 30, 2025 66.52 Mn
Dec 31, 2024 89.27 Mn
Jun 30, 2024 100.78 Mn
Dec 31, 2023 115.73 Mn
Jun 30, 2023 135.30
Dec 31, 2022 152.40 Mn
Jun 30, 2022 178.56
Dec 31, 2021 189.51 Mn
Jun 30, 2021 217.86 Mn
Dec 31, 2020 84.26 Mn
Dec 31, 2019 105.89 Mn